pcDNA3.1 human A3C
(Plasmid
#105047)
-
PurposeOverexpression of APOBEC3C in mammalian cell lines
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 105047 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA3.1
-
Backbone manufacturerInvitrogen
- Backbone size w/o insert (bp) 5428
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameAPOBEC3C (A3C)
-
SpeciesH. sapiens (human)
-
Insert Size (bp)600
-
Entrez GeneAPOBEC3C (a.k.a. A3C, APOBEC1L, ARDC2, ARDC4, ARP5, PBI, bK150C2.3)
- Promoter CMV
-
Tag
/ Fusion Protein
- HA tag (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site unknown (unknown if destroyed)
- 3′ cloning site unknown (unknown if destroyed)
- 5′ sequencing primer 5'-CGCAAATGGGCGGTAGGCGTG
- 3′ sequencing primer 5'-TAGAAGGCACAGTCGAGG (Common Sequencing Primers)
Resource Information
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pcDNA3.1 human A3C was a gift from Carsten Münk (Addgene plasmid # 105047 ; http://n2t.net/addgene:105047 ; RRID:Addgene_105047) -
For your References section:
Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1. Jaguva Vasudevan AA, Hofmann H, Willbold D, Haussinger D, Koenig BW, Munk C. J Mol Biol. 2017 Apr 21;429(8):1171-1191. doi: 10.1016/j.jmb.2017.03.015. Epub 2017 Mar 16. 10.1016/j.jmb.2017.03.015 PubMed 28315663